INO Earnings & Financial Statements
Inovio Pharmaceuticals, Inc.
$1.51
+$0.29(+24.28%)
53
Overall
60
Value
66
Tech
34
Quality
Market Cap
$156.13M
Volume
31.14M
52W Range
$0.56 - $2.72
Target Price
$5.33
INO earnings and financial statements: Inovio Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
INO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $65.3K | $217.8K | $832.0K | $10.26M | $1.77M |
| Operating income | -$86.82M | -$112.40M | -$143.94M | -$267.57M | -$301.22M |
| EBITDA | -$81.96M | -$104.51M | -$135.56M | -$270.90M | -$296.56M |
| Net income | -$84.95M | -$107.25M | -$135.12M | -$279.82M | -$303.66M |
| EPS (diluted) | $-1.81 | $-3.95 | $-6.09 | $-14.04 | $-17.40 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $74.31M | $113.20M | $170.95M | $348.53M | $495.94M |
| Total liabilities | $50.21M | $44.69M | $53.60M | $126.17M | $96.27M |
| Shareholders’ equity | $24.10M | $68.50M | $117.35M | $222.36M | $399.67M |
| Cash and equivalents | $44.27M | $65.81M | $14.31M | $46.33M | $71.14M |
| Long-term debt | $6.55M | $9.37M | $11.03M | $29.27M | $15.46M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$88.63M | -$104.08M | -$124.37M | -$216.22M | -$215.71M |
| Capital expenditure | -$285.7K | -$428.5K | -$320.9K | -$969.2K | -$1.23M |
| Free cash flow | -$88.92M | -$104.56M | -$124.69M | -$217.18M | -$216.94M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | INO | $1.51 | +24.3% | 31.14M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Inovio Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW